Repare Therapeutics Q2 2022 Earnings Report
Key Takeaways
Repare Therapeutics reported revenue of $0.7 million and a net loss of $38.1 million for the second quarter of 2022. They also entered into a worldwide license and collaboration agreement with Roche for camonsertib, receiving a $125 million upfront payment in July 2022.
Signed worldwide license and collaboration agreement with Roche for camonsertib.
Received a $125 million upfront payment from Roche in July 2022.
Advanced RP-6306, a first-in-class, oral PKMYT1 inhibitor as a monotherapy and in combinations.
Initiated IND-enabling studies for the polymerase theta inhibitor, now designated as RP-2119.
Repare Therapeutics
Repare Therapeutics
Forward Guidance
Repare Therapeutics expects to continue the clinical and preclinical development of their pipeline, including RP-6306 and RP-2119. They also anticipate potential milestone payments from the Roche collaboration and further development of product candidates using their SNIPRx platform technology.